Ovarian Cancer

Author(s):  
Shelley S. Tworoger ◽  
Amy L. Shafrir ◽  
Susan E. Hankinson

Worldwide, ovarian cancer is the seventh most commonly diagnosed cancer and the eighth most common cause of death from cancer. In 2012, 239,000 women were diagnosed with ovarian cancer and 152,000 women died of the disease worldwide. In the United States in 2015, an estimated 21,290 women were newly diagnosed with ovarian cancer and 14,180 died from the disease. Both incidence and mortality have decreased over time in the United States, with a 1.6% and 2.1% annual decrease, respectively, from 2003 to 2012. Ovarian cancers can arise from epithelial, germ, or stromal cells, although about 90% are epithelial in origin. Risk factors best confirmed to increase risk of ovarian cancer include age and a family history of ovarian cancer, while parity, oral contraceptive use, and tubal ligation decrease risk. Several etiologic pathways, including hormonal and inflammatory pathways, have garnered substantial support from both epidemiologic and laboratory studies, although many questions remain.

2017 ◽  
Vol 28 (5) ◽  
pp. 371-383 ◽  
Author(s):  
Amy L. Shafrir ◽  
Helena Schock ◽  
Elizabeth M. Poole ◽  
Kathryn L. Terry ◽  
Rulla M. Tamimi ◽  
...  

2002 ◽  
Vol 20 (22) ◽  
pp. 4485-4492 ◽  
Author(s):  
Wendy Y. Chen ◽  
Judy E. Garber ◽  
Suzanne Higham ◽  
Katherine A. Schneider ◽  
Katie B. Davis ◽  
...  

PURPOSE: BRCA1/2 genetic testing has been commercially available in the United States since 1996. Most published reports described BRCA1/2 testing as research studies at large academic centers, but less is known about testing in the community. This study evaluates the process and early outcomes of BRCA1/2 genetic testing as a clinical service in the community setting. METHODS: Surveys were mailed to women in the United States whose health care providers ordered BRCA1/2 genetic testing from Myriad Genetic Laboratories from August 1998 through July 2000. Women tested at 149 large academic centers were excluded. Main outcome measures were demographic characteristics, recall of and satisfaction with the genetic testing process, and likelihood of pursuing cancer prevention strategies. RESULTS: Among the 646 respondents, 414 (64%) had a personal history of cancer and 505 (78%) had at least one first-degree relative with breast and/or ovarian cancer. Most subjects (82%) recalled discussions of informed consent before testing (median time, 30 minutes). Genetic results were conveyed during an office visit (57%), by telephone (39%), or by mail (3%). More than 75% of respondents were “very satisfied with the counseling received.” Cancer-free subjects with a germline mutation were more likely to consider prevention strategies after receiving the genetic results. CONCLUSION: Virtually all respondents had a personal and/or family history of breast/ovarian cancer. Although pretest and posttest communications were not standardized, overall satisfaction with clinical breast cancer genetic testing was high. Additional follow-up will provide data on future cancer prevention practices and cancer incidence.


1979 ◽  
Vol 11 (S6) ◽  
pp. 119-141 ◽  
Author(s):  
Robert B. Greenblatt ◽  
Camran Nezhat ◽  
Virginia P. McNamara

The United States Food and Drug Administration and the International Planned Parenthood Federation recommend that women over the age of 40 should utilize forms of contraception other than the pill. This decision was reached as a result of the 1975 clinical papers by Mann and his associates (Mann et al., 1975; Mann & Inman, 1975) and the epidemiological reports of the Royal College of General Practitioners (1977), Mann, Inman & Thorogood (1976) and Vessey, McPherson & Johnson (1977). Several authoritative bodies believed it prudent to suggest that the age limit for oral contraceptive use be lowered to 35, and even to 30 years (Anon, 1977; Planned Parenthood memorandum, 1977). The investigations of Inman & Vessey (1968) point to a precarious rise in mortality figures for women over age 35 on oral contraceptives.


Ophthalmology ◽  
2016 ◽  
Vol 123 (4) ◽  
pp. 729-736 ◽  
Author(s):  
Ye Elaine Wang ◽  
Caitlin Kakigi ◽  
Diego Barbosa ◽  
Travis Porco ◽  
Rebecca Chen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document